NASDAQ:BLFS BioLife Solutions (BLFS) Stock Forecast, Price & News $13.17 +0.49 (+3.86%) (As of 02:44 PM ET) Add Compare Share Share Today's Range$12.70▼$13.2850-Day Range$10.81▼$20.3552-Week Range$10.48▼$26.89Volume181,363 shsAverage Volume359,326 shsMarket Capitalization$572.76 millionP/E RatioN/ADividend YieldN/APrice Target$24.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BioLife Solutions MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside88.2% Upside$24.60 Price TargetShort InterestBearish7.29% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 3 Articles This WeekInsider TradingAcquiring Shares$771,738 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.02) to $0.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.00 out of 5 starsMedical Sector652nd out of 966 stocksElectromedical Equipment Industry15th out of 22 stocks 3.5 Analyst's Opinion Consensus RatingBioLife Solutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.60, BioLife Solutions has a forecasted upside of 88.2% from its current price of $13.07.Amount of Analyst CoverageBioLife Solutions has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.29% of the outstanding shares of BioLife Solutions have been sold short.Short Interest Ratio / Days to CoverBioLife Solutions has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in BioLife Solutions has recently increased by 5.32%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioLife Solutions does not currently pay a dividend.Dividend GrowthBioLife Solutions does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLFS. Previous Next 1.9 News and Social Media Coverage News SentimentBioLife Solutions has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BioLife Solutions this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added BioLife Solutions to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioLife Solutions insiders have bought 30.44% more of their company's stock than they have sold. Specifically, they have bought $771,738.00 in company stock and sold $591,650.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of BioLife Solutions is held by insiders.Percentage Held by Institutions93.24% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioLife Solutions are expected to grow in the coming year, from ($1.02) to $0.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLife Solutions is -6.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLife Solutions is -6.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLife Solutions has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioLife Solutions (NASDAQ:BLFS) StockBioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; ultra-low temperature mechanical freezers; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.Read More BLFS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLFS Stock News HeadlinesSeptember 22, 2023 | fool.comBioLife Solutions (NASDAQ: BLFS)August 30, 2023 | seekingalpha.comBioLife Hit By An Inventory CorrectionSeptember 22, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.August 11, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: BioLife Solutions (BLFS), Synlogic (SYBX)August 11, 2023 | msn.comCraig-Hallum Maintains Biolife Solutions (BLFS) Buy RecommendationAugust 11, 2023 | finance.yahoo.comSome BioLife Solutions, Inc. (NASDAQ:BLFS) Analysts Just Made A Major Cut To Next Year's EstimatesAugust 11, 2023 | finance.yahoo.comWhy Shares of BioLife Solutions Plummeted This WeekAugust 10, 2023 | msn.comLake Street Maintains Biolife Solutions (BLFS) Buy RecommendationSeptember 22, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.August 9, 2023 | finance.yahoo.comWhy Shares of BioLife Solutions Are Slumping on WednesdayAugust 9, 2023 | finance.yahoo.comBioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Misses Revenue EstimatesAugust 8, 2023 | finance.yahoo.comBioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer BusinessJuly 28, 2023 | finance.yahoo.comBioLife Solutions to Provide Second Quarter 2023 Financial Results and Business Update on August 8, 2023July 18, 2023 | msn.comStephens & Co. Maintains Biolife Solutions (BLFS) Overweight RecommendationJuly 11, 2023 | marketwatch.comBioLife Solutions Shares Jump After New Buy RatingJuly 11, 2023 | msn.comCraig-Hallum Initiates Coverage of Biolife Solutions (BLFS) with Buy RecommendationJune 15, 2023 | seekingalpha.comBioLife: Similar Hurdles Remain, Despite Biopreservation TailwindsJune 14, 2023 | finance.yahoo.comBioLife Solutions Receives College of American Pathologists CAP-BAP Accreditation for All SciSafe® U.S. Biostorage FacilitiesJune 6, 2023 | finance.yahoo.comBioLife Solutions Launches the IntelliRate™ i67C Liquid Nitrogen (LN2) Controlled-Rate FreezerMay 16, 2023 | markets.businessinsider.comBioLife Solutions (BLFS) Gets a Buy from Maxim GroupMay 12, 2023 | finance.yahoo.comWe Think BioLife Solutions (NASDAQ:BLFS) Can Easily Afford To Drive Business GrowthMay 11, 2023 | marketwatch.com8-K: BIOLIFE SOLUTIONS INCMay 11, 2023 | finance.yahoo.comQ1 2023 BioLife Solutions Inc Earnings CallMay 10, 2023 | finance.yahoo.comBioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Misses Revenue EstimatesMay 10, 2023 | finance.yahoo.comBioLife Solutions Reports First Quarter 2023 Financial ResultsMay 9, 2023 | markets.businessinsider.comBiolife Solutions earnings: here's what Wall Street expectsMay 2, 2023 | finance.yahoo.comBioLife Solutions to Provide First Quarter 2023 Financial Results and Business Update on May 10, 2023See More Headlines Receive BLFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter. Email Address BLFS Company Calendar Last Earnings8/08/2023Today9/22/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLFS CUSIPN/A CIK834365 Webwww.biolifesolutions.com Phone(425) 402-1400Fax425-402-1433Employees466Year FoundedN/APrice Target and Rating Average Stock Price Forecast$24.60 High Stock Price Forecast$28.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+86.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,800,000.00 Net Margins-51.20% Pretax Margin-51.79% Return on Equity-9.87% Return on Assets-8.05% Debt Debt-to-Equity Ratio0.07 Current Ratio3.04 Quick Ratio2.05 Sales & Book Value Annual Sales$161.76 million Price / Sales3.54 Cash FlowN/A Price / Cash FlowN/A Book Value$8.52 per share Price / Book1.55Miscellaneous Outstanding Shares43,490,000Free Float42,316,000Market Cap$572.76 million OptionableNot Optionable Beta1.65 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Michael P. Rice (Age 60)Chairman & CEO Comp: $1.03MMr. Troy Wichterman (Age 38)Chief Financial Officer Comp: $508.89kDr. Aby J. Mathew Ph.D. (Age 51)Chairman of Scientific Advisory Board, Exec. VP & Chief Scientific Officer Comp: $543.46kMs. Karen Foster (Age 63)Chief Quality Officer Comp: $452.95kMr. Geraint PhillipsSr. VP of Global OperationsMr. Todd Berard (Age 54)Chief Marketing Officer Ms. Sarah Aebersold J.D. (Age 46)Chief HR Officer Mr. Marcus Schulz (Age 44)Chief Revenue Officer More ExecutivesKey CompetitorsOutset MedicalNASDAQ:OMZynexNASDAQ:ZYXIEdap TmsNASDAQ:EDAPAxoGenNASDAQ:AXGNSemler ScientificNASDAQ:SMLRView All CompetitorsInsiders & InstitutionsBarclays PLCBought 1,197 shares on 9/21/2023Ownership: 0.043%Michael RiceSold 1,729 sharesTotal: $19,001.71 ($10.99/share)Aby J MathewSold 519 sharesTotal: $5,703.81 ($10.99/share)Karen A FosterSold 410 sharesTotal: $4,505.90 ($10.99/share)Troy WichtermanSold 585 sharesTotal: $6,429.15 ($10.99/share)View All Insider TransactionsView All Institutional Transactions BLFS Stock - Frequently Asked Questions Should I buy or sell BioLife Solutions stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLFS shares. View BLFS analyst ratings or view top-rated stocks. What is BioLife Solutions' stock price forecast for 2023? 5 analysts have issued 1-year price objectives for BioLife Solutions' stock. Their BLFS share price forecasts range from $22.00 to $28.00. On average, they predict the company's stock price to reach $24.60 in the next year. This suggests a possible upside of 86.8% from the stock's current price. View analysts price targets for BLFS or view top-rated stocks among Wall Street analysts. How have BLFS shares performed in 2023? BioLife Solutions' stock was trading at $18.20 at the start of the year. Since then, BLFS shares have decreased by 27.6% and is now trading at $13.17. View the best growth stocks for 2023 here. Are investors shorting BioLife Solutions? BioLife Solutions saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 3,170,000 shares, an increase of 5.3% from the August 15th total of 3,010,000 shares. Based on an average daily volume of 430,800 shares, the short-interest ratio is presently 7.4 days. View BioLife Solutions' Short Interest. When is BioLife Solutions' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our BLFS earnings forecast. How were BioLife Solutions' earnings last quarter? BioLife Solutions, Inc. (NASDAQ:BLFS) posted its quarterly earnings data on Tuesday, August, 8th. The medical equipment provider reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.22. The medical equipment provider earned $39.51 million during the quarter, compared to analysts' expectations of $43.93 million. BioLife Solutions had a negative net margin of 51.20% and a negative trailing twelve-month return on equity of 9.87%. What guidance has BioLife Solutions issued on next quarter's earnings? BioLife Solutions issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $144.00 million-$158.00 million, compared to the consensus revenue estimate of $186.31 million. What is Mike Rice's approval rating as BioLife Solutions' CEO? 14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend. What other stocks do shareholders of BioLife Solutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM). What is BioLife Solutions' stock symbol? BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS." Who are BioLife Solutions' major shareholders? BioLife Solutions' stock is owned by a number of retail and institutional investors. Top institutional investors include Casdin Capital LLC (17.75%), BlackRock Inc. (12.33%), Geneva Capital Management LLC (3.59%), State Street Corp (2.65%), Palisade Capital Management LP (2.61%) and Granahan Investment Management LLC (2.17%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Geraint Phillips, Greef Roderick De, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Todd Berard, Troy Wichterman and Walter Villiger. View institutional ownership trends. How do I buy shares of BioLife Solutions? Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioLife Solutions' stock price today? One share of BLFS stock can currently be purchased for approximately $13.17. How much money does BioLife Solutions make? BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $572.76 million and generates $161.76 million in revenue each year. The medical equipment provider earns $-139,800,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. How many employees does BioLife Solutions have? The company employs 466 workers across the globe. How can I contact BioLife Solutions? BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for the company is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433. This page (NASDAQ:BLFS) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLife Solutions, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.